Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Trial Profile

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs CK 301 (Primary)
  • Indications Colorectal cancer; Endometrial cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Checkpoint Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Checkpoint Therapeutics media release, the company has expended this study by enrolling patients in additional three cohorts, intended to support requests for accelerated approval and Biologics License Application (BLA) submissions to the US FDA.
    • 20 Nov 2018 Planned number of patients changed from 80 to 500.
    • 20 Nov 2018 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top